Start the conversation
You must be logged in to post a comment.
Call it the "millennial market."
No, I'm not talking about how twenty- and thirtysomethings are affecting the market.
Instead, I'm talking about how we now measure the advance of the bellwether Dow Jones Industrial Average not by hundreds, but by thousands.
The Dow has advanced by 1,000 points five times this year... so far.
In fact, it took just 30 days for it to reach 24,000 on Nov. 30.
That's great news for just about every investor.
But the news is even better for investors like you.
For technology investors, the Nasdaq Composite set 69 new highs so far this year. It has gained 23.3%, which is 49.5% better than the S&P 500 and 15.7% better than the Dow.
Meanwhile, Bitcoin is up 1,075% in 2017 - and Ethereum has soared an amazing 5,371.4%.
And in legal marijuana, my premium Nova-X Report members have made triple-digit gains on several of the penny pot stocks in their model portfolio. To find out how to join them, just click here.
In other words, ground-floor trends like technology, cryptocurrencies, and legal marijuana are the driving forces behind the market's historic gains.
But that doesn't mean you can just blindly buy any tech stock out there and expect to make money.
While I know you don't believe that's true, some of you might buy into Wall Street's hype machine and believe you can make a fortune on some of the troubled tech leaders they're touting as "turnaround" investments in 2018.
Don't believe that hype.
Especially don't believe any hype you might hear about these 2018 "tech dogs."
These are the four stocks you want to stay as far away as possible from next year. They're dangerous - all four of them.
Take a look - and then keep away... far away...
Silicon Valley, Cryptos, and Legal Weed - Oh My!
Now then, let me be clear about something important right off the bat.
We still very much believe that the road to wealth is paved by ground-floor trends like Silicon Valley technology, cryptocurrencies, and legal marijuana. The Nasdaq's and Bitcoin's performances speak for themselves.
And I'm not saying that I expect a major correction in tech or the market in general. But when we have such a target-rich market, that's when you need to be the most careful in selecting your investments.
As we'll see in a moment, if you pick the wrong tech stock, you'll be sitting on dead money - or maybe even wipe out your net worth.
In a market like this, it is much wiser to pursue ground-floor opportunities and proven winners than the so-called "tech turnarounds" that Wall Street is trying to sell you.
Especially these four 2018 tech dogs...
2018 Tech Dog No 1: GE
If there were an award for "tech turkeys" of 2017, General Electric Corp. (NYSE: GE) would definitely make the list of finalists - and it deserves to win.
Through Dec. 4, the Nasdaq Composite had gained an amazing 23.3% - while GE managed to notch a 43.4% decline.
All that seemed to be changing in early November as Wall Street awaited word from new CEO John Flannery on his comeback plan for the global tech-industrial giant.
But after Flannery laid out his plan on Nov. 14, even longtime bulls hoping for a true turnaround were disappointed. RBC Capital Markets analyst Deane Dray was especially outspoken.
Dray said Flannery offered "very little new or bold ideas," adding that there were "no meaningful changes to the business model or quality of earnings."
The analyst cut his price target from $25 to $20 and noted that the turnaround underway will take much longer than previously thought because of deep "structural problems."
Flannery later told CNBC that he can fix the problems. That will mean selling several units. But the bad news for investors was stunning - GE is also cutting its dividend by 50% to improve its lousy cash flow.
Ouch.
Here Are 10 “One-Click” Ways to Earn 10% or Better on Your Money Every Quarter
Appreciation is great, but it’s possible to get even more out of the shares you own. A lot more: you can easily beat inflation and collect regular income to spare. There are no complicated trades to put on, no high-level options clearances necessary. In fact, you can do this with a couple of mouse clicks – passive income redefined. Click here for the report…
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.